Cargando…
Synergistic effect of PARP inhibitor and BRD4 inhibitor in multiple models of ovarian cancer
Ovarian cancer has the highest facility rate among gynaecological tumours. Current therapies including PARP inhibitors have a defect that ovarian tumour is easy to recurrent and become resistant to therapy. To solve this problem, we found that BRD4 inhibitor AZD5153 and PARP inhibitor olaparib had a...
Autores principales: | Huang, Yuhan, Liu, Chen, You, Lixin, Li, Xi, Chen, Gang, Fan, Junpeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9983312/ https://www.ncbi.nlm.nih.gov/pubmed/36753396 http://dx.doi.org/10.1111/jcmm.17683 |
Ejemplares similares
-
The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors
por: Wu, Zhaozhen, et al.
Publicado: (2021) -
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor
por: Zhang, Peng, et al.
Publicado: (2019) -
BRD4 inhibitor and histone deacetylase inhibitor synergistically inhibit the proliferation of gallbladder cancer in vitro and in vivo
por: Liu, Shilei, et al.
Publicado: (2019) -
BRD4 Inhibitor AZD5153 Suppresses the Proliferation of Colorectal Cancer Cells and Sensitizes the Anticancer Effect of PARP Inhibitor: Erratum
por: Zhang, Peng, et al.
Publicado: (2022) -
PARP inhibitors in ovarian cancer
por: Cibula, David, et al.
Publicado: (2015)